Allspring Global Investments Holdings LLC Sells 320,168 Shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX)

Allspring Global Investments Holdings LLC lessened its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 67.3% during the fourth quarter, Holdings Channel.com reports. The firm owned 155,234 shares of the biopharmaceutical company’s stock after selling 320,168 shares during the period. Allspring Global Investments Holdings LLC’s holdings in Catalyst Pharmaceuticals were worth $2,609,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently made changes to their positions in the company. American Century Companies Inc. boosted its position in shares of Catalyst Pharmaceuticals by 20.6% during the 3rd quarter. American Century Companies Inc. now owns 899,478 shares of the biopharmaceutical company’s stock worth $10,515,000 after purchasing an additional 153,697 shares in the last quarter. Vanguard Group Inc. lifted its position in Catalyst Pharmaceuticals by 2.5% in the 3rd quarter. Vanguard Group Inc. now owns 7,046,487 shares of the biopharmaceutical company’s stock valued at $82,373,000 after acquiring an additional 174,739 shares in the last quarter. Illinois Municipal Retirement Fund bought a new position in Catalyst Pharmaceuticals in the 3rd quarter valued at about $711,000. Charles Schwab Investment Management Inc. lifted its position in Catalyst Pharmaceuticals by 6.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 921,327 shares of the biopharmaceutical company’s stock valued at $10,770,000 after acquiring an additional 58,018 shares in the last quarter. Finally, Swiss National Bank lifted its position in Catalyst Pharmaceuticals by 1.8% in the 3rd quarter. Swiss National Bank now owns 222,500 shares of the biopharmaceutical company’s stock valued at $2,601,000 after acquiring an additional 4,000 shares in the last quarter. Institutional investors own 79.22% of the company’s stock.

Catalyst Pharmaceuticals Stock Down 1.4 %

Catalyst Pharmaceuticals stock opened at $15.13 on Friday. Catalyst Pharmaceuticals, Inc. has a 52 week low of $11.09 and a 52 week high of $17.76. The company’s 50 day moving average price is $15.41 and its two-hundred day moving average price is $14.55. The stock has a market cap of $1.79 billion, a P/E ratio of 24.80, a P/E/G ratio of 0.84 and a beta of 0.89.

Catalyst Pharmaceuticals (NASDAQ:CPRX) last posted its earnings results on Wednesday, February 28th. The biopharmaceutical company reported $0.49 EPS for the quarter, topping the consensus estimate of $0.45 by $0.04. Catalyst Pharmaceuticals had a net margin of 17.93% and a return on equity of 26.56%. The firm had revenue of $110.57 million for the quarter, compared to analysts’ expectations of $105.78 million. On average, equities analysts anticipate that Catalyst Pharmaceuticals, Inc. will post 1.81 EPS for the current year.

Insider Transactions at Catalyst Pharmaceuticals

In other news, insider Brian Elsbernd sold 25,000 shares of the firm’s stock in a transaction that occurred on Wednesday, March 27th. The shares were sold at an average price of $16.44, for a total transaction of $411,000.00. Following the completion of the sale, the insider now owns 124,433 shares in the company, valued at approximately $2,045,678.52. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. 12.10% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

CPRX has been the topic of several recent research reports. StockNews.com raised shares of Catalyst Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Thursday, March 21st. Oppenheimer reaffirmed an “outperform” rating and issued a $29.00 price target on shares of Catalyst Pharmaceuticals in a research report on Wednesday, March 27th. Citigroup initiated coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 14th. They issued a “buy” rating and a $27.00 price target on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $24.00 price target on shares of Catalyst Pharmaceuticals in a research report on Friday, March 1st. Finally, Bank of America assumed coverage on shares of Catalyst Pharmaceuticals in a research report on Thursday, March 7th. They issued a “buy” rating and a $23.00 price target on the stock. Six research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $26.43.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, an amifampridine phosphate tablets for the treatment of patients with lambert-eaton myasthenic syndrome (LEMS); and Ruzurgi for the treatment of pediatric LEMS patients.